News Gilead rescinds orphan status request for COVID-19 drug Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market.
News Shire plans filing for HAE drug after phase 3 success Lanadelumab could revolutionise treatment of swelling disease.
News EUSA Pharma approval fills gap in neuroblastoma market Company can move in after United Therapeutics withdrew its product Unituxin
News EU regulators back two more orphan drugs, question of pricin... Two orphan medicines are heading towards the European market, after regulators recommended rare disease drugs from Biogen and BioMarin.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends